Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Press Barbados.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on May 8, 2025
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announces its financial results for the …
Oculis Reports Q1 2025 Financial Results and Provides Company Update
GlobeNewswire
·
May 8, 2025
The recent R…
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
GlobeNewswire
·
May 8, 2025
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted …
Taysha Gene Therapies to Release First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15
GlobeNewswire
·
May 8, 2025
DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system ( …
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 8, 2025
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non- …
Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025; Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call …
Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical …
Senseonics Holdings, Inc. Reports First Quarter Financial Results
GlobeNewswire
·
May 8, 2025
Q1 Revenue of $6.3 million, growth year over year of 24% Partnership with Sequel integrates twiist™ automated insulin delivery (AID) system with Eversense® 365 one-year continuous glucose monitor (CGM); twiist with Eversense 365 launch expected in Q3 …
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance
GlobeNewswire
·
May 8, 2025
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives …
Fulcrum Therapeutics to Participate in Upcoming May Conferences
GlobeNewswire
·
May 8, 2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 8, 2025
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data …
Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
GlobeNewswire
·
May 8, 2025
● Q1 Revenue of $11.5 million; a 13% increase year-over-year ● Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ● Q1 Thyroid test volume up 16% year-over-year to record levels ● Q1 Thyroid revenue of $8.0M; up …
Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …
CVRx Reports First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 8, 2025
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …
TOMI Environmental Solutions, Inc. Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its …
SIGA Reports Financial Results for Three Months Ended March 31, 2025
GlobeNewswire
·
May 8, 2025
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW …
Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
GlobeNewswire
·
May 8, 2025
- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting …
BeautyHealth Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
LONG BEACH, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”). “ …
Profound Medical Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of …
Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
GlobeNewswire
·
May 8, 2025
REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its …